home / stock / allk / allk articles
NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Allakos, Inc. ("Allakos" or the "Co...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 350 points on Tuesday. The Dow traded down 0.93% to 37,...
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the ...
Shares of Allakos Inc (NASDAQ: ALLK) were climbing in early trading on Monday. Despite past setbacks, lirentelimab has a “strong chance&rdquo...
JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid im...
Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday. Allakos Inc. ...
Over the past twenty days of trading, Allakos Inc. (NASDAQ: ALLK), from August 08, 2022 to September 08, 2022 there is a potential Short Squeeze ab...
News, Short Squeeze, Breakout and More Instantly...
Allakos Inc. Company Name:
ALLK Stock Symbol:
NASDAQ Market:
SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results f...
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...